Dr. Maya Halperin is the Medical Director of NeuroRx where she oversees the company’s clinical development programme, including the Phase III development of its lead combination product NRX100/101 for the treatment of Biopolar Depression.
Prior to this position, Dr. Halperin was Chief Medical Officer and Executive Director of Galmed where she was responsible for taking Aramchol™, a first in class, orally active, liver targeted SCD – 1 modulator for the treatment of NASH, through multiple clinical trials to gaining Fast Track designation status from the FDA.
She was previously Medical Director of Teva Pharmaceutical where she took several products through clinical development to launch.
Dr. Halperin holds a Medical Degree from Hadassah Medical School, the Hebrew University, Jerusalem and an M.A. in philosophy from the Tel Aviv University.